AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

The randomized eSMARTER trial found that people who received Alzheimer’s genetic results through a digital platform had anxiety, disease-specific distress and knowledge scores that met noninferiority criteria compared with people who received results by clinician-led telehealth. Similar findings were reported for optional p-tau217 result disclosure. The trial does not establish that every patient or every digital results system will have the same experience.

A randomized trial found that receiving Alzheimer’s genetic results through a digital platform did not produce worse short-term anxiety, disease-specific distress or disease-related knowledge scores than receiving the information in a clinician-led telehealth appointment. The eSMARTER findings, presented by Jessica Langbaum of the Banner Alzheimer’s Institute at the Clinical Trials on Alzheimer’s Disease conference in Boston and published in JAMA Neurology, also showed similar results when participants received optional blood biomarker information.

Gift ideaOffer from Amazon

Give the gift of listening to someone who needs a break

  • Choose a 1-, 3-, 6- or 12-month membership
  • They pick the audiobooks they love
  • Easy to send by email
Give Audible Delivered by email · No shipping needed
As an affiliate, we earn on qualifying purchases.

The study randomized 651 participants to receive APOE genetic results: 435 through the digital platform and 216 during a telehealth session with a study clinician. Researchers assessed anxiety, Alzheimer’s-related distress and knowledge one to seven days after disclosure; scores in the digital group met the trial’s noninferiority criteria compared with telehealth. Similar findings were reported after participants were offered disclosure of plasma p-tau217 results.

The groups did not show overall differences in Alzheimer’s-related knowledge, anxiety symptoms or disease-specific distress after APOE disclosure. Among participants who carried an APOE4 variant, researchers did observe some small differences: telehealth recipients had a greater short-term reduction in disease-specific distress and slightly higher satisfaction, while the digital group had a higher mean negative response to learning about APOE risk. The reported differences were small and did not persist longitudinally; satisfaction was high in both groups.

Participants were ages 60 to 80, had previously completed APOE genotyping through the GeneMatch research program without receiving the result, passed psychological screening and had internet access. Their mean age was 68, and 67% were women. Most participants receiving APOE results were carriers: 58% were heterozygotes and 10% homozygotes; 32% were noncarriers. Participants could review optional educational materials before disclosure.

At a glance
reportWhen: Presented November 21, 2026, at the Cli…
The developmentResearchers reported that digital delivery of Alzheimer’s APOE and p-tau217 test results met noninferiority criteria against clinician-led telehealth for several patient-reported outcomes.

Digital Results Could Reach Patients Sooner

The findings address a practical gap between the availability of test results and access to a clinician who can explain them. Under the 21st Century Cures Act, most medical test results, including Alzheimer’s genetic and biomarker findings, must be made available to patients immediately. Patients may see results in a portal before a scheduled follow-up, sometimes as a static report or PDF with little explanation.

Langbaum said the results support the possibility of using a patient-centered digital platform to give people information and context when results become available. If health systems can provide clear explanations and educational resources digitally, patients may have an alternative to waiting for an appointment to understand the information. The trial supports digital disclosure as an option under the study conditions; it does not show that a digital tool can replace clinician support in every case.

De’Longhi All-in-One Espresso and Coffee Maker with 10-Cup Pot and Milk Frother

De’Longhi All-in-One Espresso and Coffee Maker with 10-Cup Pot and Milk Frother

As an affiliate, we earn on qualifying purchases.

How the eSMARTER Trial Worked

Earlier research cited by the study found that disclosure of Alzheimer’s biomarkers was generally safe and well tolerated, but clinicians led disclosure in person or by telehealth. The eSMARTER trial tested whether a digital method could produce comparable outcomes to a clinician-mediated telehealth visit. APOE results were disclosed first; six months later, participants could choose to receive their plasma p-tau217 results using the method assigned to them.

The trial focused on measured outcomes after disclosure, including anxiety, disease-specific distress and knowledge. Its participants had already enrolled in a research program and passed psychological screening, and all had internet access. Those features matter when interpreting how closely the results may apply to patients outside a research setting.

“We found that learning Alzheimer’s genetic and biomarker information from a digital platform is no less effective — in other words, no worse than — receiving this information from a clinician telehealth visit.”

— Jessica Langbaum, PhD, Banner Alzheimer’s Institute

Limits on Applying the Findings

The results do not establish how digital disclosure would work for people who lack internet access, were not screened for psychological risk, or have different clinical or support needs. The study enrolled people already involved in GeneMatch, so they had previously agreed to genetic testing even though their APOE results had not been disclosed. The supplied report does not give enough detail to assess how particular platform features, such as clinician contact options or the presentation of risk, shaped responses.

Noninferiority means the digital approach met the study’s specified standard for not being worse on the measured outcomes; it does not mean the two methods were identical or that no participant experienced distress. The reported short-term differences among APOE4 carriers were small, but individual reactions may vary. The material provided also does not specify the exact noninferiority margins or provide detailed outcome estimates.

Testing Tools in Patient Portals

Langbaum said the findings could inform development of digital platforms that plug into patient portals and explain Alzheimer’s genetic and biomarker results. The report does not identify a launch date, a specific product or a health system committed to adopting such a tool. Further work would need to establish how digital disclosure performs in broader patient populations and how people can obtain help when results raise questions or concerns.

For now, the reported result is evidence from one randomized study that digital disclosure was an acceptable alternative to telehealth for the outcomes measured in this selected group. Whether health systems adopt the approach, and what safeguards or clinician follow-up they provide, remains to be determined.

Key Questions

What did the eSMARTER trial find?

The trial found that digital disclosure of APOE results met noninferiority criteria compared with clinician-led telehealth for anxiety, disease-specific distress and Alzheimer’s-related knowledge. Similar results were reported for optional p-tau217 disclosure.

Does this mean digital results caused no distress?

No. The finding means the digital method was not worse than telehealth under the trial’s noninferiority standard on the measured outcomes. It does not mean no participant felt distress, and some small short-term differences appeared among APOE4 carriers.

What are APOE and p-tau217?

APOE is a gene for which certain variants are associated with Alzheimer’s risk. Plasma p-tau217 is a blood biomarker discussed in the study. The trial examined how participants responded to disclosure of these results; the report does not present the tests as a diagnosis on their own.

Who took part in the study?

The 651 participants were 60 to 80 years old, had previously completed APOE genotyping through GeneMatch without receiving their results, passed psychological screening and had internet access. The group’s mean age was 68, and 67% were women.

Will Alzheimer’s results now be delivered digitally?

The findings do not announce a change in clinical practice or a new patient-portal service. Langbaum said the results could support development of digital tools, but the source report does not identify a launch plan or a health system adopting one.

Source: medpagetoday.com

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

Pluralibacter Gergoviae Shampoo Recall

A major shampoo brand recalls products after detection of Pluralibacter gergoviae bacteria. Consumers advised to stop use immediately.

Mässlingslarm På Barnsjukhus I Stockholm – SVT Nyheter

Ett mässlingslarm har utlösts på ett barnsjukhus i Stockholm, enligt SVT Nyheter. Det är oklart hur många som påverkas och vilka åtgärder som vidtas.

Patient Navigators: An Important Senior Resource

Patient navigators can help seniors coordinate care and find services. Learn what they do, where to find one and what Medicare may cover.

A Controversial Alzheimer’s Surgery Is Said To Reverse Symptoms

A new, controversial surgical procedure for Alzheimer’s is reported to reverse symptoms in some patients, raising questions about safety and efficacy.